Panacea Bio's DengiAll completes Phase III trial enrollment
Panacea Biotec's share price surged 6% after completing enrollment for its Phase III dengue vaccine trial. The indigenous DengiAll vaccine targets a 2027 launch. Read more for stock impact and trial details.